ShareValue scores for VVVV: Valuation 50, Quality 42, Growth 50, Health 41.

VVVV
NYSE

vVARDIS Holding AG

$15.00(-3.04%)

Updated

Loading chart...
Sentiment

Pulse

Rating

Moderate

Trap Risk

P/E to median

Not enough data
Valuation
50
Fair Value
Price vs Value
Quality
42
Moderate
Business Strength
Growth
50
Moderate
Revenue & Earnings
Health
41
Moderate
Financial Stability
Price trend
N/A
N/a
Separate from the four scores

Company Details

About

vVARDIS Holding AG, a dental medtech company, develops and provides non-invasive cavity treatment products in Switzerland and the United States. The company offers the Curodont platform, including Curodont Repair, a biomimetic system to arrest and reverse early caries through enamel regeneration; Curodont Protect, a remineralising tooth gel containing the biomimetic Oligo-Peptide 103 technology; and Enamel Serum, enriched with peptides and hydroxyapatite, which delivers calcium and phosphate ions to care for the enamel. The company was incorporated in 2020 and is based in Zug, Switzerland. vVARDIS Holding AG operates as a subsidiary of VVARDIS Investment Holding AG.

Score Analysis

AI Investment Thesis

Powered by DeepSeek. For research only. Not financial advice.

Sources:[1][2][3]

Our model rates vVARDIS Holding AG as fairly valued versus its sector, though its 57.6 P/S sits roughly 11 times the 5.1 sector average, a gap the market's post-IPO repricing partly reflects.

Data as of:Nov 20, 2026

By using ShareValue.ai you agree to our Terms and Privacy Policy. Educational platform, not investment advice.